Aurobindo Pharma USA Recalls Northstar Label Gabapentin Capsules Due to Empty Capsule Reports

Aurobindo Pharma USA, Inc has issued a voluntary recall of one lot of gabapentin capsules, USP 300 mg, 100-count bottles to the consumer level after finding that some capsules were empty.

Aurobindo Pharma USA, Inc, of Dayton, NJ, has issued a voluntary recall of one lot (Lot Number GESB14011-A) of gabapentin capsules, USP 300 mg, 100-count bottles to the consumer level after finding that some capsules were empty. Empty capsules could result in missed doses and adverse health consequences that may include short-term reduction in efficacy, short-term withdrawal effect, or status epilepticus that could be life-threatening, a

firm press release

posted to the Food and Drug Administration (FDA) website indicates. The product was distributed through the Northstar label to retail outlets nationwide. The company is notifying distributors and customers via recall letters and is arranging for return of the product. Adverse reactions may be reported to FDA’s

MedWatch

Safety Information and Adverse Event Reporting Program.